Loading
Treatment given to keep a fast-growing cancer in check during the weeks between deciding on CAR-T (or transplant) and actually receiving it, while the cells are being manufactured or a donor found.
Aggressive lymphomas and leukaemias can progress or cause organ damage in the 3-6 weeks it takes to manufacture autologous CAR-T cells, so patients often receive bridging chemotherapy, steroids, radiotherapy to bulky sites, or bispecific antibodies; response to bridging and low disease burden at infusion predict better CAR-T outcomes and less CRS. Bridging must avoid drugs that harm T cells before apheresis and be timed so its toxicity has cleared before lymphodepletion. Its necessity is a strong argument for faster manufacturing and off-the-shelf allogeneic products; in the ZUMA-7 trial design, permitting bridging chemotherapy was a point of methodological debate.
Showing the technology this term belongs to: CAR-T cell therapy.
Shares Lymphodepletion before CAR-T, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, JULIET, Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma.
Shares Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, JULIET, Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma, ZUMA-7.
Shares Salvage therapy, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, JULIET, Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma.
Shares Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma, ZUMA-7, CAR-T cell therapy.
Shares Vein-to-vein time and manufacturing slots, CAR-T cell therapy.
Shares Intermediate hepatocellular carcinoma (BCLC B), Early hepatocellular carcinoma (BCLC 0 and A).
Shares Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, JULIET, ZUMA-7, CAR-T cell therapy.
Shares Apheresis (leukapheresis), Salvage therapy, Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma, ZUMA-7.